Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
3.79
USD
|
+6.46%
|
|
+2.71%
|
+79.62%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
271.7
|
493.7
|
392.8
|
922.6
|
1,146
|
2,232
|
-
|
-
|
Enterprise Value (EV)
1 |
271.7
|
493.7
|
392.8
|
922.6
|
1,162
|
2,090
|
2,111
|
1,896
|
P/E ratio
|
-3.78
x
|
-5.68
x
|
-3.49
x
|
-6.54
x
|
-6.59
x
|
-11
x
|
-22.3
x
|
79.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
591
x
|
1,951
x
|
282
x
|
1,548
x
|
4,835
x
|
41.1
x
|
9.69
x
|
4.95
x
|
EV / Revenue
|
591
x
|
1,951
x
|
282
x
|
1,548
x
|
4,902
x
|
38.5
x
|
9.16
x
|
4.21
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-6
x
|
-9.75
x
|
-39.6
x
|
12.1
x
|
EV / FCF
|
-6,141,168
x
|
-2,870,530
x
|
-3,382,983
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
2.01
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
199,778
|
310,472
|
321,949
|
381,235
|
543,064
|
588,874
|
-
|
-
|
Reference price
2 |
1.360
|
1.590
|
1.220
|
2.420
|
2.110
|
3.790
|
3.790
|
3.790
|
Announcement Date
|
3/12/20
|
3/11/21
|
3/10/22
|
3/16/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.46
|
0.253
|
1.393
|
0.596
|
0.237
|
54.24
|
230.4
|
450.8
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-193.5
|
-214.3
|
-53.35
|
156.4
|
EBIT
1 |
-72.5
|
-76.91
|
-114
|
-138.6
|
-193.9
|
-217.9
|
-101.9
|
66.86
|
Operating Margin
|
-15,761.96%
|
-30,400.4%
|
-8,183.7%
|
-23,246.64%
|
-81,832.91%
|
-401.66%
|
-44.25%
|
14.83%
|
Earnings before Tax (EBT)
1 |
-68.55
|
-75.62
|
-116.1
|
-141.9
|
-184.1
|
-214.1
|
-96.37
|
47.5
|
Net income
1 |
-68.55
|
-75.62
|
-116.1
|
-141.9
|
-184.1
|
-214.4
|
-110.5
|
44.05
|
Net margin
|
-14,901.74%
|
-29,888.14%
|
-8,335.39%
|
-23,808.89%
|
-77,690.72%
|
-395.26%
|
-47.96%
|
9.77%
|
EPS
2 |
-0.3600
|
-0.2800
|
-0.3500
|
-0.3700
|
-0.3200
|
-0.3460
|
-0.1700
|
0.0475
|
Free Cash Flow
|
-44.24
|
-172
|
-116.1
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-9,617.83%
|
-67,973.12%
|
-8,334.82%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/11/21
|
3/10/22
|
3/16/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
0.109
|
1.04
|
0.123
|
0.073
|
0.297
|
0.103
|
0.021
|
0.029
|
0.164
|
0.023
|
0.0288
|
0.0288
|
19.06
|
35.12
|
53.05
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-25.67
|
-30.98
|
-28.68
|
-27.98
|
-39.95
|
-41.95
|
-40.09
|
-51.95
|
-47.61
|
-54.29
|
-59.6
|
-66.14
|
-52.16
|
-39.96
|
-43.76
|
Operating Margin
|
-23,554.13%
|
-2,979.04%
|
-23,313.01%
|
-38,323.29%
|
-13,450.51%
|
-40,729.13%
|
-190,914.29%
|
-179,141.38%
|
-29,031.71%
|
-236,039.13%
|
-206,723.31%
|
-229,412.07%
|
-273.62%
|
-113.78%
|
-82.5%
|
Earnings before Tax (EBT)
1 |
-26.7
|
-32.02
|
-30.1
|
-28.12
|
-41.05
|
-42.64
|
-38.12
|
-49.23
|
-44.8
|
-51.97
|
-58
|
-65.47
|
-51.34
|
-39.29
|
-
|
Net income
1 |
-26.7
|
-32.02
|
-30.1
|
-28.12
|
-41.05
|
-42.64
|
-38.12
|
-49.23
|
-44.8
|
-51.97
|
-57.9
|
-65.08
|
-51.2
|
-40.2
|
-41.76
|
Net margin
|
-24,492.66%
|
-3,078.56%
|
-24,469.92%
|
-38,516.44%
|
-13,821.89%
|
-41,393.2%
|
-181,533.33%
|
-169,748.28%
|
-27,320.12%
|
-225,973.91%
|
-200,838.02%
|
-225,730.84%
|
-268.59%
|
-114.48%
|
-78.72%
|
EPS
2 |
-0.0800
|
-0.1000
|
-0.0900
|
-0.0700
|
-0.1000
|
-0.1000
|
-0.0700
|
-0.0900
|
-0.0800
|
-0.0900
|
-0.0960
|
-0.1060
|
-0.0840
|
-0.0620
|
-0.0500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/9/21
|
3/10/22
|
5/9/22
|
8/11/22
|
11/3/22
|
3/16/23
|
5/11/23
|
8/3/23
|
11/2/23
|
2/28/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
15.9
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
142
|
121
|
335
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-0.082
x
|
-
|
-
|
-
|
Free Cash Flow
|
-44.2
|
-172
|
-116
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
0.6800
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.41
|
0.4
|
0.21
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
89.78%
|
158.5%
|
14.86%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/11/21
|
3/10/22
|
3/16/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
3.79
USD Average target price
5.083
USD Spread / Average Target +34.12% Consensus |
1st Jan change
|
Capi.
|
---|
| +79.62% | 2.23B | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|